Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher, Aspetrics, Sinopec, Epidauros, Luminex, Nanogen, Nanosphere, MDS, ABI, Agilent, Qiagen

Thermo Fisher Inks Mass Spec, LIMS Collaborations
 
Thermo Fisher Scientific this week announced two separate collaborations with Aspetrics and Sinopec.
 
Thermo said that Aspetrics is including Thermo’s GRAMS spectroscopy software in its new encoded photometric near infrared process analyzer. Terms of the deal were not disclosed.
 
Thermo also said that petrochemical firm Sinopec, China’s largest company, has signed a contract to standardize on Thermo’s laboratory information management systems, chromatography data systems, and desktop spectroscopy software. Terms of that pact also were not disclosed.
 

 
Epidauros Licenses Biomarker Patents to Luminex, Nanogen, and Nanosphere
 
Epidauros said this week that it has signed non-exclusive licensing agreements for its biomarker patents with Luminex Molecular Diagnostics, Nanogen, and Nanosphere.
 
The agreements will allow the companies to use Epidauros' CYP2D6 IP, which is involved in metabolism of roughly 25 percent of “the most commonly prescribed drugs,” as a predictive marker for responsiveness and adverse drug reactions, the company said.
 
Financial terms of the agreement were not disclosed.
 

 
MDS Completes Acquisition of Molecular Devices
 
MDS said this week that it had completed the acquisition of Molecular Devices.
 
In January, the companies had agreed to a deal under which MDS would buy Molecular Devices for $615 million in cash, or $35.50 a share for all of Molecular Devices’ common stock (see BioCommerce Week 1/31/2007).
 
Molecular Devices and MDS’ Sciex unit have been combined into a business unit called MDS Analytical Technologies. The new unit is led by MDS Sciex President Andy Boorn.
 
According to MDS, Molecular Devices and MDS Sciex combined brought in 2006 revenue of $432 million.
 

 
ABI Declares Quarterly Dividend, Stock Upgraded
 
Applied Biosystems has declared a regular quarterly dividend of $.0425 per share.
 
The dividend will be payable on July 2, ABI parent Applera said this week.
 
Also this week, investment bank JP Morgan upgraded ABI’s stock to “neutral” from “underweight.”
 
ABI’s shares closed up 1.2 percent at $30.08 for the week ended Tuesday.
 

 
Agilent to Accelerate Share-Repurchase Program
 
Agilent Technologies said last week that its board of directors had authorized an acceleration in the firm’s existing $2 billion share-repurchase program.
 
Thus far, Agilent has repurchased roughly $500 million of the shares. Agilent expects to complete the $2 billion program by the end of this fiscal year, which ends Oct. 31.
 
Agilent said that once this program has been completed it will have repurchased $6.4 billion worth of its stock since 2005.
 

 
Qiagen Shares Upgraded
 
Investment bank Deutsche Securities last week raised its rating on Qiagen’s stock to “buy” from “hold.”
 
Shares in Qiagen closed up 3.6 percent at $16.98 for the week ended Tuesday.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.